News Column

New Solid Cancer Study Findings Have Been Reported from Federal University

June 2, 2014



By a News Reporter-Staff News Editor at Clinical Oncology Week -- A new study on Oncology is now available. According to news originating from Goiania, Brazil, by NewsRx correspondents, research stated, "Dextran-functionalized maghemite fluid (DexMF) has been tested to treat Ehrlich-solid-tumor-bearing mice, evidencing its potential use in mediating magnetohyperthermia in breast cancer treatment. However, although magnetic nanoparticles tend to accumulate in tumor tissues, part of the nanomaterial can reach the blood stream, and then the organism."

Our news journalists obtained a quote from the research from Federal University, "The aim of this study was to investigate the acute systemic effects of the intratumoral injection of DexMF mediating magnetohyperthermia in the treatment of an advanced clinical Ehrlich-solid-tumor, assessed through histopathological analyses of liver, kidneys, heart and spleen, comet assay, micronucleus test, hemogram, and serum levels of bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, creatinine, and urea. The tumor's histopathology and morphometry were used to assess its aggressiveness and regression. DexMF mediating hyperthermia was effective in containing tumor aggressiveness and in inducing tumor regression, besides showing no toxic effects."

According to the news editors, the research concluded: "Its physical characteristics also suggest that it is safe to use in other biomedical applications."

For more information on this research see: Dextran-functionalized magnetic fluid mediating magnetohyperthermia for treatment of Ehrlich-solid-tumor-bearing mice: toxicological and histopathological evaluations. Tumor Biology, 2014;35(4):3391-3403. Tumor Biology can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Tumor Biology - www.springerlink.com/content/1010-4283/)

The news correspondents report that additional information may be obtained from A.L. Miranda-Vilela, Univ Fed Goias, Inst Chem, Goiania, Go, Brazil. Additional authors for this research include K.R. Yamamoto, K.L.C. Miranda, B.N. Matos, M.C. de Almeida, J.P.F. Longo, J. de Souza, J.M.S. Fernandes, P.P.C. Sartoratto and Z.G.M. Lacava (see also Oncology).

Keywords for this news article include: Brazil, Goiania, Oncology, South America, Solid Cancers

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Oncology Week